Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites

Chu, Ki‐Back; Quan, Fu‐Shi

doi:10.1007/82_2021_232

Cited by 10 publications

(4 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, we have generated a virus-like particle (VLP) vaccine expressing the ROP4 antigen of T. gondii ( Kang et al., 2019 ). However, high production costs and the requirement for extensive downstream purification processes are the main issues of this vaccine platform ( Effio and Hubbuch, 2015 ; Chu and Quan, 2021 ). Compared to VLPs, rBVs can be rapidly manufactured in large quantities at cheaper production costs, thus enabling these to be suitable vaccine platforms ( Kis et al., 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Mucosal Administration of Recombinant Baculovirus Displaying Toxoplasma gondii ROP4 Confers Protection Against T. gondii Challenge Infection in Mice

Yoon

Chu

Kang

et al. 2021

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

Pathogens require physical contact with the mucosal surface of the host organism to initiate infection and as such, vaccines eliciting both mucosal and systemic immune responses would be promising. Studies involving the use of recombinant baculoviruses (rBVs) as mucosal vaccines are severely lacking despite their inherently safe nature, especially against pathogens of global importance such as Toxoplasma gondii. Here, we generated rBVs displaying T. gondii rhoptry protein 4 (ROP4) and evaluated their protective efficacy in BALB/c mice following immunization via intranasal (IN) and oral routes. IN immunization with the ROP4-expressing rBVs elicited higher levels of parasite-specific IgA antibody responses compared to oral immunization. Upon challenge infection with a lethal dose of T. gondii ME49, IN immunization elicited significantly higher parasite-specific antibody responses in the mucosal tissues such as intestines, feces, vaginal samples, and brain than oral immunization. Marked increases in IgG and IgA antibody-secreting cell (ASC) responses were observed from intranasally immunized mice. IN immunization elicited significantly enhanced induction of CD4+, CD8+ T cells, and germinal center B (GC B) cell responses from secondary lymphoid organs while limiting the production of the inflammatory cytokines IFN-γ and IL-6 in the brain, all of which contributed to protecting mice against T. gondii lethal challenge infection. Our findings suggest that IN delivery of ROP4 rBVs induced better mucosal and systemic immunity against the lethal T. gondii challenge infection compared to oral immunization.

show abstract

Section: Introductionmentioning

confidence: 99%

Mucosal Administration of Recombinant Baculovirus Displaying Toxoplasma gondii ROP4 Confers Protection Against T. gondii Challenge Infection in Mice

Yoon

Chu

Kang

et al. 2021

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some members of this family, such as the Cydia pomonella Granulovirus (CpGV), have even been approved in the European Union (EU) under Regulation (EC) No 1107/2009 as active substance for insect pest control. Furthermore, baculoviruses are widely used as expression systems for the production and characterization of recombinant proteins, multi-protein complexes like virus-like particles and vaccines in insect cells (Chu & Quan 2021;Grose et al 2021). Bombyx mori nucleopolyhedrovirus (BmNPV) or Autographa californica multiple nucleopolyhedrovirus (AcMNPV) are commonly used viral vectors for protein expression in several Lepidopteran cell lines.…”

Section: Baculovirusmentioning

confidence: 99%

Engineering strategies for insect viruses and microbes for dsRNA production and delivery to insects for targeted gene silencing

Xue¹,

Santos²,

Smagghe³

et al. 2023

entomologia

View full text Add to dashboard Cite

RNA interference (RNAi)-based pest control is viewed as a safe and effective method for insect pest control. However, the stability and efficient cellular delivery of the double stranded RNA (dsRNA) active molecule remains crucial to its success in pest control. Among the different approaches that have been proposed to improve dsRNA delivery in insects, the use of nano-carriers, engineered viruses and engineered microbes have been successfully employed in proofof-concept studies. This review focuses on engineering approaches that have been successfully employed to modify insect viruses and different microbes for dsRNA production and delivery in insects. First, the different viral vector systems based on insect RNA and DNA viruses for dsRNA delivery are discussed. Second, a comprehensive overview of different microbe-based (bacteria, fungi, microalgae) dsRNA production and delivery systems that have been developed till date are presented. Finally, future perspectives on the development of other delivery systems with potential in the context of insect pest control are provided. Overall, this review is expected to stimulate awareness, interest, insight and research into promising sources of biotechnologically interesting viruses and microbes for protecting agriculture and human health against insect pests.

show abstract

“…However, these particles are inherently safe due to the lack of genetic material. Molecular and structural factors that contribute to the high immunogenicity of VLP-based vaccines have been described in detail [ 32 ], and as such, these aspects will be briefly described. In VLPs, antigens of interest are repetitively presented in a dense array which is critical to mounting efficient immune responses against the target antigen [ 33 , 34 ].…”

Section: Virus-like Particle (Vlp) Vaccinesmentioning

confidence: 99%

Recent progress in vaccine development targeting pre-clinical human toxoplasmosis

Chu,

Quan

2023

Parasites Hosts Dis

Self Cite

View full text Add to dashboard Cite

Toxoplasma gondii is an intracellular parasitic organism affecting all warm-blooded vertebrates. Due to the unavailability of commercialized human T. gondii vaccine, many studies have been reported investigating the protective efficacy of pre-clinical T. gondii vaccines expressing diverse antigens. Careful antigen selection and implementing multifarious immunization strategies could enhance protection against toxoplasmosis in animal models. Although none of the available vaccines could remove the tissue-dwelling parasites from the host organism, findings from these pre-clinical toxoplasmosis vaccine studies highlighted their developmental potential and provided insights into rational vaccine design. We herein explored the progress of T. gondii vaccine development using DNA, protein subunit, and virus-like particle vaccine platforms. Specifically, we summarized the findings from the pre-clinical toxoplasmosis vaccine studies involving T. gondii challenge infection in mice published in the past 5 years.

show abstract

Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites

Cited by 10 publications

References 160 publications

Mucosal Administration of Recombinant Baculovirus Displaying Toxoplasma gondii ROP4 Confers Protection Against T. gondii Challenge Infection in Mice

Mucosal Administration of Recombinant Baculovirus Displaying Toxoplasma gondii ROP4 Confers Protection Against T. gondii Challenge Infection in Mice

Engineering strategies for insect viruses and microbes for dsRNA production and delivery to insects for targeted gene silencing

Recent progress in vaccine development targeting pre-clinical human toxoplasmosis

Contact Info

Product

Resources

About